On Tuesday, Nektar Therapeutics (NASDAQ:NKTR)’s shares inclined 0.80% to $12.57.
Nektar Therapeutics (NKTR) formerly approved, subject to stockholder approval, an amendment to the Company’s 2012 Performance Incentive Plan (the “2012 Plan”) that would enhance the number of shares of the Company’s common stock reserved for issuance under the 2012 Plan by an additional 7,000,000 shares. According to the final results from the Company’s 2015 Annual Meeting of Stockholders held on June 16, 2015 (the “Annual Meeting”), the Company’s stockholders approved the amendment to the 2012 Plan. The foregoing description of the amendment is qualified in its entirety by reference to the text of the amended and restated version of the 2012 Plan, which is filed as Exhibit 10.1 hereto and incorporated herein by reference.
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline comprises drug candidates in therapeutic areas comprising oncology, pain, anti-infectives, and immunology.
Franklin Resources, Inc. (NYSE:BEN)’s shares dropped -0.31% to $51.16.
Franklin Resources, Inc. (BEN) declared a quarterly cash dividend in the amount of $0.15 per share payable on July 15, 2015 to stockholders of record holding shares of common stock at the close of business on June 30, 2015. The quarterly dividend of $0.15 per share is equivalent to the dividend paid for the prior quarter and represents a 25% enhance over the quarterly dividend paid for the same quarter last year.
Alcatel-Lucent provides Internet protocol (IP) and cloud networking, and ultra- broadband access worldwide. The company’s Core Networking segment offers IP routing, carrier Ethernet, network functions virtualization, and software defined networking applications and infrastructure to meet the challenges of network traffic growth while supporting the delivery of cloud-enabled business, mobile, and residential services for service providers, mobile network operators, cable/multiple system operators, transportation, utilities, and large-scale enterprises.
At the end of Tuesday’s trade, Foot Locker, Inc. (NYSE:FL)‘s shares surged 1.50% to $65.85.
Foot Locker, Inc. (FL) the New York-based specialty athletic retailer, declares its partnership with ASICS America Corporation to launch its “Real Lives. Real Runners.” campaign, ahead of the 2015 TCS New York City Marathon. Whether it’s a mile or a marathon, all runners have a story, and this campaign will provide a platform to capture and share their stories.
Building on the successful 2014 “All Runners Welcome” campaign from Foot Locker and ASICS, “Real Lives. Real Runners.” invites filmmakers to identify authentic runners and document in a short film why they run and how running impacts their lives. The winning film will air nationally during the television broadcast of the 2015 TCS New York City Marathon, and the winning filmmaker will receive a cash prize from MOFILM, plus an all-expenses paid trip to Los Angeles for the annual MOFILM Awards.
Filmmakers can submit up to a three-minute piece, celebrating runners from all walks of life, with shortened versions of 30 and 60 seconds. Deadline for submissions is Sept. 7, 2015. For more information, entrants should visit MOFILM.com.
Foot Locker, Inc. operates as an athletic shoes and apparel retailer. The company operates in two segments, Athletic Stores and Direct-to-Customers. The Athletic Stores segment retails athletic footwear, apparel, accessories, and equipment under various formats, counting Foot Locker, Lady Foot Locker, Kids Foot Locker, Champs Sports, Footaction, and SIX:02, in addition to Runners Point, and Sidestep. As of January 31, 2015, it operated 3,423 primarily mall-based stores in the United States, Canada, Europe, Australia, and New Zealand. The Direct-to-Customers segment sell athletic footwear, apparel, equipment, team licensed products, and private-label merchandise through Internet Websites, mobile sites, and catalogs.
IsoRay, Inc. (NYSEMKT:ISR), ended its Tuesday’s trading session with 3.97% gain, and closed at $1.57.
IsoRay, Inc. (ISR) declared the appointment, on June 18, 2015, of Michael (Mick) McCormick, former Executive Vice President of Global Sales and Marketing of Columbia Sportswear, to its Board of Directors.
Mr. McCormick will serve on the Audit and Compensation Committees of the Board, and will chair the Nominating and Corporate Governance Committee of the Board.
IsoRay, Inc develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces Proxcelan Cesium-131 brachytherapy seeds for the treatment of prostate, lung, head and neck, colorectal, brain, pelvic/abdominal, and gynecological cancers, in addition to ocular melanoma. It also offers GliaSite radiation therapy system, a balloon catheter device, which is used to treat brain cancer, counting primary and recurrent gliomas and metastic brain tumors.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
